PQM130 |
Catalog No.GC36954 |
Le PQM130, un composé hybride Feruloyl-Donepezil À pénétration cérébrale, est un candidat médicament multicible contre la neurotoxicité induite par l'oligomère Aβ1-42 (AβO) et présente une activité anti-inflammatoire.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2089415-51-8
Sample solution is provided at 25 µL, 10mM.
PQM130, a Feruloyl-Donepezil Hybrid compound with brain penatration, is a multitarget drug candidate against the neurotoxicity induced by Aβ1-42 oligomer (AβO) and shows anti-inflammatory activity. PQM130 acts as a neuroprotective compound for anti-AD drug development[1].
PQM130 (0.5-1 mg/kg, i.p., daily for 10 days) treatment after the i.c.v. AβO injection reduces oxidative damage and neuroinflammation and induces cell survival and protein synthesis through the modulation of GSK3β and extracellular signal-regulated kinases (ERK1/2) [1]. Animal Model: Adult male C57Bl/6 mice (9 weeks old, 25-30 g body weight) [1].
[1]. Morroni F, et al. PQM130, a Novel Feruloyl-Donepezil Hybrid Compound, Effectively Ameliorates the Cognitive Impairments and Pathology in a Mouse Model of Alzheimer's Disease. Front Pharmacol. 2019 Jun 12;10:658.
Average Rating: 5
(Based on Reviews and 11 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *